Recognizing the Early and Subtle Signs and Symptoms of Rett Syndrome

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Hope for Rett Syndrome: Novel Treatment Approaches

Recognizing the Early and Subtle Signs and Symptoms of Rett Syndrome

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT. 

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including Pediatric Neurologists, Pediatricians, Primary Care Physicians, Nurse Practitioners and Physician Assistants, involved in the management of patients with Rett Syndrome (RTT).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Learn to clearly communicate information that is pertinent to the successful management of RTT through each stage of the disease
    • Increase the ability to recognize the subtle signs and symptoms of RTT earlier
    • Differentiate the pharmacodynamics and latest efficacy and safety clinical trial data associated with FDA-approved treatment for RTT
    • Educate clinicians concerning the role of interprofessional team members in optimizing collaboration and communication to ensure patients with RTT receive high-quality care that leads to enhanced patient outcomes and improvements in quality of life
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Jeffrey L. Neul MD, PhD, faculty for this educational event, is a contracted researcher for Acadia Pharmaceuticals; has ownership interest in Alcyone Theraputics; and receives consulting fees from NeuroGene, Alcyone, Hoffman-La Roche, and Taysha Gene Therapies.  

    Alan K. Percy, MD, faculty for this educational event, is a contracted researcher for Acadia Pharmaceuticals, NIH/NICHD; and receives consulting fees from Acadia, Neurogene, and Taysha.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Canan Schumann, PharmD/PhD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Acadia Pharmaceuticals, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, LLC.

  • Fee Statements

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 5/26/2023 through 5/26/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Apr 2024